Benchmark raised the firm’s price target on Ligand (LGND) to $175 from $160 and keeps a Buy rating on the shares. A recent successful $460M convertible bond offering “adds ammunition to the company’s royalty monetization and project finance efforts,” the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND:
- Ligand Pharma’s Strong Financial Position and Strategic Initiatives Justify Buy Rating
- Positive Outlook for Ligand Pharma: FDA Approval and Strategic Expansion Drive Growth Potential
- Ligand price target raised to $206 from $157 at H.C. Wainwright
- Ligand Pharma Completes $460M Convertible Notes Offering
- Ligand Pharmaceuticals Inc. Reports Strong Q2 Earnings